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Abstract
We used a standardized screening tool to examine frequency of depression and its relation to antiretroviral medi-
cation adherence among HIV-infected persons on highly active antiretroviral therapy (HAART) in the Study to
Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study). This is a prospective
observational cohort of 700HIV-infected patients enrolled betweenMarch 2004 and June 2006 in fourU.S. cities, who
completed a confidential audio computer-assisted self-interview [ACASI] with behavioral risk and health-related
questions at baseline and 6-month follow-up visits, including the nine-question PRIME-MDdepression screener and
a validated 3-day antiretroviral adherence question. Among 539 eligible participants receiving HAART, 14% had
depression at baseline (22% women, 12% men). In multivariable analysis using generalized estimating equations
(GEE) to account for repeatedmeasurements through 24months of follow-up, personswho reported depression on a
given ACASI were twice as likely to report nonadherence to antiretrovirals on the same ACASI (Odds ratio [OR]
2.02, 95% CI: 1.15, 3.57] for mild/moderate depression versus none); such persons were also less likely to have HIV
viral load< 400 copies/mL. Self-administered computerized standardized screening tools can identify at-risk indi-
viduals with depression who may benefit from interventions to improve antiretroviral adherence.
Introduction
Depression occurs frequently in HIV-infected per-sons. Reported rates of depression and depressive
symptoms range from 22 to 54 percent in HIV-infected com-
munities in the United States and typically exceed the prev-
alence found in the general population.1–6
The frequency of depression does not appear to vary ac-
cording to the use of highly active antiretroviral therapy
(HAART). In both the pre and post HAART era, depression as
well as other disorders of anxiety anddysthymia are common.6–8
Despite the high prevalence of depression and depres-
sive symptoms among HIV-infected persons, these condi-
tions remain under-diagnosed.9,10 For these individuals, the
consequences of unrecognized and untreated depression can
be significant and include increased mortality, diminished
quality of life, and impaired adherence to antiretroviral
therapy.11–18 A recent meta-analysis documented an associa-
tion between depression and nonadherence to antiretroviral
therapy across different study populations, including some
that represented diverse and contemporary HIV cohorts with
a significant representation of women and persons of color.19
As the current U.S. HIV epidemic disproportionately impacts
communities of color, the relationship of gender and ethnicity
to depression is important to document and understand.20–26
Depression and depressive symptoms do seem to occur
more frequently in HIV-infected women compared to
men.3,15,16 Women living with HIV infection often have many
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sociodemographic and lifestyle characteristics associatedwith
depression, such as poverty, isolation, higher rates of smok-
ing, traumatic life events, and substance abuse.2,27–30 Several
reports indicate that cellular immune responses in women
may be altered with depression.29 Fortunately, treatment of
depression pharmacologically or through other behavioral
interventions can be beneficial with demonstrated improved
clinical outcomes and HAART adherence;12,31–36 however,
differential use of antidepressants has been documented.37–39
The relationship of depression and its treatment and
HAART adherence is a dynamic one and longitudinal eval-
uations of HIV-infected persons in the evolving chronic
disease model of care are needed. Assessing depression in
HIV-infected persons can be done through structured inter-
views or standardized screening instruments that may be self-
administered or done electronically.19,40–45 The PRIME-MD
Patient Health Questionnaire-9 (PHQ-9) is a widely used in-
strument for depression screening that has been incorporated
into primary care settings to identify the presence and severity
of depression.43,45,46 The ease of its administration enables the
PHQ-9 to be used in long-term patient cohorts.
Using longitudinal data from the prospective SUN Study, a
cohort of contemporary HIV-infected U.S. adults, we sought
to examine the frequency and associated demographic, clini-
cal, laboratory, and behavioral correlates of depression
among participants prescribed HAART and followed for 24
months, and to evaluate the association between depression
and adherence to HAART during the same period.
Methods
The SUN Study
The SUN Study is an ongoing, closed, prospective cohort
study of 700 HIV-infected patients receiving care at HIV-
specialty clinics inDenver, Colorado;Minneapolis,Minnesota;
Providence, Rhode Island; and St. Louis, Missouri. Partici-
pants were enrolled between March 2004 and June 2006, and
were followed for up to 24 months thereafter. Detailed meth-
ods and inclusion criteria have been described elsewhere.47
The study protocol was approved and has been reviewed
annually by the institutional review boards of the Centers for
Disease Control (CDC) and all participating institutions. All
participants provided written, informed consent.
Study population
We restricted all analyses to HAART-treated participants
to examine risk factors for depression and the association
between depression and antiretroviral medication (ARV)
adherence within the same subset of participants followed
from baseline up to 24-month study visit. Of 700 SUN Study
participants, 539 were prescribed HAART and completed the
baseline Audio Computer-Assisted Self Interview (ACASI)
survey. The remaining patients were not included in this
study because they did not complete a baseline ACASI survey
data (n = 23) or were currently not prescribed HAART or were
ARV-naı¨ve (n = 138).
Measures
SUNStudy participants completed anACASI at enrollment
(baseline) and every 6 months thereafter; not all participants
completed ACASI at all timepoints. Information collected by
ACASI included sociodemographic factors, education, em-
ployment status, tobacco, alcohol and drug use, sexual risk
behaviors, depressive symptoms, suicidal ideation, quality of
life, and adherence to antiretroviral medications. The ACASI
questionnaire could be taken in English or Spanish. To ensure
participant confidentiality and encourage self-disclosure of
accurate information, participants listened to questions alone
while logged onto a dedicated computer terminal in a private
area. All data collected from the ACASI were held confiden-
tially and not shared with the participants’ healthcare pro-
viders. For this analysis, we examined ACASI data from
baseline through the 24-month study visit, as available. In
addition, we abstracted CD4 T-lymphocyte cell counts (CD4),
plasma HIV-1 RNA viral loads (HIV VL), diagnoses of de-
pression and hepatitis C infection, and prescriptions given for
antiretroviral and antidepressant medication from partici-
pants’ medical records.
Definitions of the outcome variables
Depression by PRIME-MD. Depression was assessed
using the Patient Health Questionnaire (PHQ-9), also known
as PRIME-MD, which is a series of nine questions regarding
the frequency of depressive symptoms over the last 2 weeks
that has been validated for diagnosis of depression
(Table 1).43,45,46 Each question has four possible responses:
‘‘not at all,’’ ‘‘several days,’’ ‘‘more than half the days,’’ and
‘‘nearly every day.’’ Each response was scored from 0 to 3,
Table 1. PRIME-MD Instrument
for Depression Screening
Depression Screening Questions
Over the past 2 weeks, how often have you been bothered by
any of the following problems....?
1. Little interest or pleasure in doing things
2. Feeling down, depressed or hopeless
3. Trouble falling or staying asleep, or sleeping too much
4. *Feeling tired or having little energy
5. Poor appetite or overeating
6. Feeling bad about yourself—or that you are a failure or
have let yourself or your family down
7. Trouble concentrating on things such as reading the
newspaper or watching television
8. Moving or speaking so slowly that other people could
have noticed? Or the opposite-being so fidgety or restless
that you have been moving around a lot more than usual
9. Thoughts that you would be better off dead or hurting
yourself in some way.
*This question was omitted from the ACASI, in error, through the
end of 2006. For analyses at these time points, we instead used a
question in the ACASI asked in the following way: ‘‘How often in
the last 4 weeks have you had a lot of energy?’’ and coded that
variable in reverse fashion in the following manner:
0 All the time (tired= 0)
1 Most of the time (tired= 0)
2 A good bit of the time (tired= 0)
3 Some of the time (tired= 1)
4 A little of the time (tired= 2)
5 None of the time (tired= 3)
Sensitivity analyses at 24 months for participants who had both
original question #4 and substitute question, revealed that the
distribution of total depression scores was similar, and 96.5% (274/
284) of participants had concordant level of depression severity
(none, mild, moderately severe, severe).
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respectively. The total score could range from 0 to 27.
Depression severity was defined as none/minimal (total score
0–4), mild (total score 5–9), moderate (total score 10–14),
moderately severe (total score 15–19), and severe (total score
20–27), as previously reported.43,45,46 We defined major de-
pression as (1) a score of 2 or 3 on four of the nine items,
including on each of the screener’s first two items; or (2) a
score of 2 or 3 on five of the nine items, including on at least
one of the screener’s first two items. Based on each patient’s
score at baseline or at any one of the subsequent 6-monthly
ACASI evaluations, the patient was assigned a binary de-
pression outcome (yes or no) for his or her depression status at
that point in time; thus depression status could vary over time
(e.g., new onset, resolution, or intermittent depression).
Adherence to antiretroviral medication. Adherence to
antiretroviral medication was assessed from self-report on the
ACASI. Nonadherence was defined as having missed one or
more doses of prescribed antiretroviral medications in the
past 3 days.
Definitions of predictor variables and other covariates
Participants’ age, hepatitis C co-infection status (defined by
either serostatus or presence of the clinical diagnosis in the
medical records if serostatus was absent), marital status, and
type of health insurance were determined at the baseline SUN
Study visit. Employment status, drinking 3 or more alcoholic
drinks per day in the past 30 days, current tobacco use (‘Do
you currently smoke cigarettes?’), nonprescription drug use
in the past 6 months (an aggregate variable for use of cocaine,
heroin, injected drugs, methamphetamines, poppers, mari-
juana, erectile dysfunction agents, or a club or party drugs
[e.g., gamma hydroxybutarate, ketamine]), family history of
depression were updated every 6 months based on interval
ACASI responses. Receipt of antidepressants, CD4 count, and
HIV VL were updated every 6 months based on data ab-
stracted from the medical records. Two clinicians reviewed
the medical records to confirm that antidepressant medica-
tions were prescribed for depression and not other uses (e.g.,
neuropathy, smoking cessation). HAART was defined as a
regimen comprised of ‡ 3 nucleoside reverse transcriptase
inhibitors or ‡ 3 antiretroviral drugs from at least 2 different
classes, as per SUN Study inclusion criteria.47
For repeated measures analyses (see Statistical Analyses
section, below), the closest value for each 6-month predictor
variable was taken from the same 6-month ACASI evaluation
as the binary outcome variable for depression status (yes/no)
at that point in time. For the plasma HIV VL and CD4 count,
the closest values from medical chart abstraction (within 12
months before up to 3 months after) to the 6-month ACASI
were used.
Statistical analyses
First, we described sociodemographic and clinical factors
associated with depression at baseline according to baseline
PRIME-MD score, overall and stratified by sex. Univariate
differences were assessed using the chi-square test (discrete
variables) or the Wilcoxon rank sum test (continuous vari-
ables). The chi-square test was used to test for trend. Second,
we performed two sets of longitudinal regression analyses: (i)
to identify patient-level factors associatedwith depression at a
given ACASI evaluation, and (ii) to assess the association of
depression with nonadherence each defined at a given ACASI
evaluation, and adjusted for other patient-level covariables.
For both of these regression analyses we used data from the
baseline, 6-, 12-, 18- and 24-month ACASI, as available.
To account for the correlation between repeated ACASI
interview results for each participant, we used generalized
estimating equations (GEE) models, assuming a binomial
distribution for each of two outcome variables (depression,
adherence) in separate models; for each model, results
are reported as an odds ratio (OR) with associated 95%
confidence interval (CI). Variables possibly associated
(p< 0.10) with the outcome of interest in the univariate
analyses were included in multivariable models; separate
models were constructed for the outcomes of depression
and non-adherence.
We constructed separate models for predictors of depres-
sion in women and men, because in exploratory analyses the
associations between risk factors and depression varied by
sex, as did the prevalence of depression. By contrast, we
combined data from men and women when modeling the
association between depression and adherence, because we
did not observe marked differences in associations by sex.
We did not include HIV RNA (viral load, VL) as a predictor
variable in themodels for depression and nonadherence aswe
hypothesized it to be an outcome of depression and non-
adherence rather than a predictor (i.e., reverse causal rela-
tionship). Final models were obtained by backward selection
and retained only predictor variables with a p value < 0.05.
Finally, we also described the association between prevalent
depression severity and the likelihood of having a suppressed
HIV VL (i.e.,< 400 copies/mL) at that point in time. Analyses
were repeated using a viral suppression threshold of < 50
copies/mL after excluding the minority of patients who had
their viral load measured with assays with a lower limit of
detection of < 400 copies/mL and who had undetectable re-
sults (i.e., censored, non-evaluable data). All analyses were




Of 539 participants, 21.2% were women, 60.9% white,
26.7% non-Hispanic black and 8.2% Hispanic (Table 2).
Overall, 75 (13.9%) participants had symptoms of depression
at baseline. Depression was more prevalent among women
(21.9%) compared with men (11.8%, p= 0.005) and among
non-Hispanic blacks (17.4%) andHispanics (29.6%) compared
with non-Hispanic whites (10.7%) (race/ethnicity overall
comparison, p= 0.003). The prevalence of depression at base-
line by sex and race/ethnicity is displayed in Fig. 1.
Other baseline characteristics associated with depression
(Table 2) included having no marital/sexual partner, hetero-
sexual, or intravenous-drug-use (IDU) risk for HIV trans-
mission versus men who have sex with men (MSM) risk,
hepatitis C co-infection, use of public insurance, and current
tobacco use. There was a decreasing frequency of depression
with increasing extent of employment; retired or other status
(27.3%), unemployed (21.9%), part-time employed (8.1%),
and full-time employed (6.1%) ( p< 0.001). Depression was
more frequent among participants with a family history of
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Table 2. Baseline Characteristics of the Study Population and Prevalence of Depression
for HAART-Treated Participants, the SUN Study, 2004–2006
Total No depression Depressiona
N= 539 N = 464 N= 75
n (%) n (%) n (%)
% with
depression p Value
Age (baseline), years 0.136
< 35 113 (21.0) 101 (21.8) 12 (16.0) 10.6
35–44 231 (42.9) 191 (41.2) 40 (53.3) 17.3
‡ 45 195 (36.2) 172 (37.1) 23 (30.7) 11.8
Sex 0.005
Male 425 (78.9) 375 (80.8) 50 (66.7) 11.8
Female 114 (21.2) 89 (19.2) 25 (33.3) 21.9
Race/ethnicity 0.003
Non-Hispanic black 144 (26.7) 119 (25.7) 25 (33.3) 17.4
Hispanic 44 (8.2) 31 (6.7) 13 (17.3) 29.6
Other, or unknown 23 (4.3) 21 (4.5) 2 (2.7) 8.7
Non-Hispanic white 328 (60.9) 293 (63.2) 35 (46.7) 10.7
Marital status 0.152
Married 71 (13.2) 63 (13.6) 8 (10.7) 11.3
Single without a partner 260 (48.2) 217 (46.8) 43 (57.3) 16.5
Single with partner 92 (17.1) 82 (17.7) 10 (13.3) 10.9
Divorced, widowed or separated 63 (11.7) 43 (9.3) 10 (13.3) 18.9
Unknown 63 (11.7) 59 (12.7) 4 (5.3) 6.4
Partner status 0.017
Alone 313 (58.1) 260 (56.0) 53 (70.7) 16.9
Partner, or unknown 226 (41.9) 204 (44.0) 22 (29.3) 9.7
Employment status < 0.001
Full time 262 (48.6) 246 (53.0) 16 (21.3) 6.1
Part time 62 (11.5) 57 (12.3) 5 (6.7) 8.1
Unemployed 96 (17.8) 75 (16.2) 21 (28.0) 21.9
Retired or other 119 (22.1) 86 (18.5) 33 (44.0) 27.3
HIV risk group 0.016
Heterosexual 132 (24.5) 107 (23.1) 25 (33.3) 18.9
IDU 36 (6.7) 27 (5.8) 9 (12.0) 25.0
MSM 322 (59.8) 289 (62.3) 33 (44.0) 10.3
Other 49 (9.1) 41 (8.8) 8 (10.7) 16.3
Insurance status 0.043
Private 219 (40.6) 196 (42.2) 23 (30.7) 10.5
Public 178 (33.0) 144 (31.0) 34 (45.3) 19.1
Other, or unknown 142 (26.4) 124 (26.7) 18 (24.0) 12.7
Tobacco use (current) < 0.001
Yes 233 (43.2) 182 (39.2) 51 (68.0) 21.9
No 306 (56.8) 282 (60.8) 24 (32.0) 7.8
Drug use past 6 months 0.108
Yes 277 (51.4) 232 (50.0) 45 (60.0) 16.3
No 262 (48.6) 232 (50.0) 30 (40.0) 11.5
Alcohol use past 30 days 0.879
< 3 drinks per day 392 (72.7) 338 (72.8) 54 (72.0) 13.8
3 or more drinks per day 147 (27.3) 126 (27.2) 21 (28.0) 14.3
BMI (median), kg/m2 25.6 (22.8,29.0) 25.6 (22.8, 29.0) 25.8 (22.5, 30.0) 0.713
< 25 240 (44.5) 210 (45.3) 30 (40.0) 12.5 0.350
25–29.9 195 (36.2) 169 (36.4) 26 (34.7) 13.3
‡ 30 104 (19.3) 85 (18.3) 19 (25.3) 18.3
CD4 (median), cells/mm3 455 (296,675) 465 (299, 680) 403 (239, 596) 0.058
< 200 60 (11.2) 51 (11.0) 9 (12.2) 15.0 0.440
200–349 129 (24.0) 108 (23.3) 21 (28.4) 16.3
350–500 120 (22.4) 101 (21.8) 19 (25.7) 15.8
> 500 228 (42.5) 203 (43.8) 25 (33.8) 11.0
HIV viral load < 400 cp/mL
Yes 476 (88.6) 414 (89.4) 62 (83.8) 13.0 0.156
No 61 (11.4) 49 (10.6) 12 (16.2) 19.7
Median VL (log10 cp/mL) if viremic 3.2 (2.9,4.3) 3.3 (2.9,4.1) 3.2 (3.1,4.7) 0.814
Hepatitis C co-infection 0.001
Yes 72 (13.4) 53 (11.4) 19 (25.3) 26.4
No 467 (86.6) 411 (88.6) 56 (74.7) 12.0
(continued)
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depression, and among participants prescribed antidepres-
sants within 6 months prior to baseline. Participants who re-
ported nonadherence to ARVs were more likely to have
depression than participants who did not or who were miss-
ing adherence data (23.1% vs. 12.3% vs. 14.3%, p = 0.04). There
were no significant differences in the frequency of depression
at baseline according to age, marital status, illicit or non-
prescribed recreational drug use, body mass index (BMI),
CD4 count, or HIV VL.
Longitudinal correlates of depression
Of 539 patients who had baseline ACASI data available,
383 (71.1%) completed an ACASI at the 24-month study visit;
the remaining 156 (28.9%) participants were not surveyed
because theywere lost to care (e.g., transferred to another HIV
clinic), died, or missed the 24-month study visit and did not
complete the ACASI. Among patients who completed the 24-
month study visit, 54 (14.1%) reported depression at baseline,
compared with 21 (13.5%) among patients who did not
complete the 24-month visit ( p= 0.84). Overall, 75 (13.9%) and
41 (10.7%) participants, at the baseline and 24-month visit,
respectively, reported depression by ACASI.
Among 539 patients included, 403 (74.8%) reported no
depression at baseline or during available follow-up visits
through 24 months (‘no evidence of depression’); 61 (11.3%)
reported no depression at baseline but depression on at least
one follow-up visit (‘potential depression onset’); 44 (8.2%)
reported depression at baseline and no depression on one or
more follow-up visits (‘intermittent or resolved depression’);
Table 2. (Continued)
Total No depression Depressiona
N = 539 N= 464 N = 75
n (%) n (%) n (%)
% with
depression p Value
Family history of depression < 0.001
Yes 180 (33.4) 140 (30.2) 40 (53.3) 22.2
No 351 (65.1) 317 (68.3) 34 (45.3) 9.7
Missing 8 (1.5) 7 (1.5) 1 (1.3) 12.5
Prescribed antidepressant in the past 6 months
No 397 (73.7) 361 (77.8) 36 (48.0) 9.1 < 0.001
Yes 142 (26.3) 103 (22.2) 39 (52.0) 27.5
Missed dose of ARVs in the past 3 days 0.041
Yes 78 (14.5) 60 (12.9) 18 (24.0) 23.1
No 454 (84.2) 398 (85.8) 56 (74.7) 12.3
Missing 7 (1.3) 6 (1.3) 1 (1.3) 14.3
Time since HIV diagnosis (baseline) 0.801
< 5 years 266 (49.4) 230 (49.6) 36 (48.0) 13.5
‡ 5 years 273 (50.6) 234 (50.4) 39 (52.0) 14.3
aDepression was defined based on the results from PRIME-MD screen, as described in the methods. ARV, antiretroviral therapy; BMI, body
mass index; HCV, hepatitis C virus; IDVU, injection drug users; MSM, men who have sex with men.
FIG. 1. Frequency of depression at baseline among HAART-experienced participants in the SUN Study, by sex and race/
ethnicity, 2002–2006 (n= 539).
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and 31 (5.8%) reported depression at baseline and on all their
follow-up visits through 24 months (‘persistent depression’).
In sex-specific univariate analyses for the 114 women and
425 men included in our analysis, the following factors were
significantly associated with depression for both sexes during
the 24 months of observation on HAART: unemployed or
retired employment status versus employed part or full time,
use of public insurance versus other forms of insurance or no
insurance, current tobacco use, hepatitis C co-infection, a
family history of depression, and receipt of antidepressant
medication in the past 6 months (Table 3). Furthermore,
among women, age 35 years and older, Hispanic race/eth-
nicity compared with non-Hispanic white, illicit or non-
prescribed recreational drug use, as well as CD4 count< 200
Table 3. Longitudinal Correlates of Depression by PRIME-MD, Baseline
to 24 Months of Observation in the SUN Study, 2004–2008










< 35 Referent Referent Referent
35–44 3.89 (2.01, 7.50) 2.19 (1.08, 4.46)c 1.45 (0.91, 2.34)
‡ 45 2.91 (1.45, 5.84) 1.46 (0.68, 3.17) 1.54 (0.95, 2.47)
Race/ethnicity
White Referent Referent Referent Referent
Black 1.29 (0.74, 2.22) 1.61 (0.88, 2.92) 1.86 (1.30, 2.66) 2.03 (1.40, 2.94)c
Hispanic, other, or unknown 2.29 (1.18, 4.46) 3.43 (1.60, 7.37)c 1.56 (0.99, 2.44) 1.75 (1.10, 2.78)c
Partner statusa (baseline)
Partner or unknown Referent Referent Referent
No partner 1.62 (0.94, 2.78) 1.71 (1.25, 2.34) 1.47 (1.06, 2.03)c
Employment status (closestb)
Full, part time Referent Referent
No job, retired, or other 18.20 (7.22, 45.87) 6.14 (4.41, 8.55)
Insurance status (baseline)
Private, other, or unknown Referent Referent
Public 1.60 (1.01, 2.54) 1.77 (1.29, 2.42)
Current tobacco use (current)
No Referent Referent Referent Referent
Yes 5.85 (3.93, 10.09) 5.38 (3.01, 9.64)c 2.43 (1.79, 3.30) 2.24 (1.64, 3.07)c
Drug use in last 6 months
No Referent Referent
Yes 2.05 (1.27, 3.29) 1.23 (0.91, 1.66)
Alcohol use past 30 days
< 3 drinks per day Referent Referent
3 or more drinks per day 1.58 (0.91, 2.75) 1.20 (0.88, 1.68)
BMI, kg/m3
< 25 Referent Referent
25–29.9 0.78 (0.44, 1.37) 1.06 (0.77, 1.47)
‡ 30 0.60 (0.35, 1.03) 0.86 (0.53, 1.40)
CD4 count (closestb)cells/mm3
< 200 3.50 (1.66, 7.37) 3.84 (1.67, 8.81)c 1.67 (0.95, 2.92)
200–349 1.49 (0.81, 2.74) 1.36 (0.70, 2.62) 1.36 (0.91, 2.04)
350–500 1.48 (0.83, 2.64) 1.32 (0.70, 2.49) 1.37 (0.95, 1.99)
> 500 Referent Referent Referent
HCV (baseline)
No Referent Referent
Yes 3.51 (2.14, 5.74) 2.62 (1.79, 3.83)
Family history of depression (closest)
No/unknown Referent Referent Referent
Yes 1.89 (1.19, 2.97) 1.91 (1.41, 2.60) 1.96 (1.42, 2.69)c
Prescribed antidepressant in the past 6 months
No Referent Referent
Yes 3.17 (1.53, 6.58) 2.64 (1.67, 4.17)
Duration since HIV diagnosis (baseline)
< 5 years Referent Referent
‡ 5 years 1.57 (0.99, 2.48) 0.75 (0.56, 1.02)
aIncludes marital status. Persons married or with a partner are categorized as having a partner; b‘‘Closest’’: means that data for this variable
were taken from the same (6-monthly) ACASI evaluation as the data for the depression outcome; for VL and CD4, take closest values from
the medical record (-1 year to+ 3 month window). cStatistically significant association at p < 0.05.
BMI, body mass index; OR, odds ratio.
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versus ‡ 500 cells/mm3, were associated with depression. In
men, non-Hispanic black race/ethnicity and no marital/
sexual partner were also associated with depression. In the
multivariable sex-specific analysis, a number of factors re-
mained independently associated with risk of depression in
both groups, but certain further distinctions emerged. Among
women, depression was significantly associated with age
35–44 years compared with age < 35 years, Hispanic ethnicity
or other/unknown race compared with non-Hispanic white
race/ethnicity, current tobacco use, and CD4 count < 200
cells/mm3 compared with ‡ 500 cells/mm3. Among men,
factors associated significantly with depression included
black race and Hispanic ethnicity, having no marital/sexual
partner, current tobacco use, and family history of depression.
Association between depression
and nonadherence to ARVs
Nonadherence to ARVs was reported by 78 (14.5%) of the
539 participants at baseline and 60 (15.7%) of the 383 partici-
pants at the 24-month visit. Among participants with a 24-
month visit, 52 (13.6%) reported nonadherence to ARVs at
baseline compared with 26 (16.7%) among patients who did
not go on to complete a 24-month visit ( p = 0.38). In univariate
longitudinal analysis, depression of any severity on anACASI
assessment was associated with approximately twofold
higher odds of nonadherence on the same ACASI assessment
(Table 4). Other factors associated with nonadherence in uni-
variate analyses were female sex, non-white race or Hispanic
ethnicity, heterosexual and IDU risk group compared with
MSM, unemployment, public insurance, tobacco use, illicit
drug use, consumption of 3 ormore alcoholic drinks daily, HIV
diagnosis‡ 5 years, and CD4 count< 200 cells/mm3 compared
with‡ 500 cells/mm3.
In themultivariable longitudinal analysis, participants who
reported mild or moderate levels of depression and persons
who reported moderately severe or severe depression had
higher odds of nonadherence (OR 2.02, 95% CI 1.15–3.57 and
OR 1.74, 95% CI 1.19–2.56, respectively) than participants
who were not depressed (Table 4). Other factors that re-
mained independently associated with nonadherence were
female sex, non-Hispanic black and Hispanic or other race/
ethnicity, tobacco use, consuming ‡ 3 alcoholic drinks daily,




At baseline, the prevalence of viral suppression (HIV
VL < 400 copies/mL) among the 537 participants was 88.6%:
viral suppressionwas 89.4% among the 464 personswhowere
not depressed, 84.2% among the 19 persons who were mildly
or moderately depressed, and 83.6% among the 56 moder-
ately severely or severely depressed (test for trend p = 0.17). In
all time points after baseline, patients who reported any level
of depression had lower rates of virologic suppression (Fig. 2)
Discussion
This analysis based on data from a confidential self-
administered computerized standard screening instrument
administered to a contemporary and sociodemographically
diverse cohort of HIV-infected patients in care extends pre-
vious findings that depression is prevalent, but not uniformly
distributed, among HIV-infected US patients in the HAART
era. We also found, as have others, a concerning association of
depression with nonadherence to antiretroviral therapy and
with lower levels of virologic suppression over 24 months of
follow-up.
Similar to the general population, HIV-infected SUN Study
participants who were most likely to be diagnosed as de-
pressed were women and persons of color (Hispanics and
African-Americans).4 For ethnic minorities in the US, the
complex interaction of poverty, lifetime trauma, chronic ill-
ness, and illicit drug use result in a syndemic of HIV infection
and mental illness.48,49 We found that current tobacco smok-
ing was associated with depression, potentially because to-
bacco use has been associated with poor socioeconomic and
psychosocial status. Factors such as unemployment and
having public health insurance, both of which are also gen-
erally associated with lower socioeconomic status, were as-
sociated with depression in the crude longitudinal analyses,
although they were not independently associated after ad-
justment for sex and race.
Among the most prevalent co-morbid chronic illnesses in
HIV-infected adults that can increase the risk for depression
and poor clinical outcomes is hepatitis C infection. Hepatitis C
infection itself leads to recognized neurologic sequelae in-
cluding depression.50 In our baseline analysis, the frequency
of depression was high among HIV-infected participants co-
infected with hepatitis C (26.4%). Hepatitis C co-infection was
not associated with depression in multivariable analyses in
our study, but has been independently prognostic of depres-
sion in other HIV cohorts.51,52
We performed separate analyses by sex to elucidate factors
associated with the high rates of depression in women. While
Hispanics and non-Hispanic blacks were more likely to be
depressed overall, Hispanic women had the highest rates of
depression (as shown in Fig. 1). What accounts for the higher
rate in Hispanics may not be discernible in the study, al-
though the possibility that the computerized PHQ screening
instrument in Spanish actually identified more depressed
women is an intriguing possibility. Women with CD4 counts
below 200 cells/mm3, those using tobacco, and the ‘‘middle-
aged’’ group of 35- to 44-year-olds were among those most
likely to be depressed. Among the already vulnerable, these
depressed womenmay be at particular risk to be nonadherent
to medication. The interplay with depression and adherence
at lower CD4 strata can result in a cycle of more symptomatic
HIV disease or disease progression.53,54 In the Women’s In-
teragency HIV Study, depression, early discontinuation of
HAART, low income, illicit drug use and smoking were as-
sociated with worse clinical outcomes.55
In the present analysis, we found that nonadherence to
HAART over 24-months of follow-up was also associated
with depression, after controlling for other independent risk
factors that included female sex, being a person of color, re-
tired or ‘other’ (not full- or part-time) employment status,
tobacco use, drinking 3 or more alcoholic beverages per day,
having been diagnosed with HIV infection ‡ 5 years ago, and
a CD4 cell count < 200 versus > 500 cells/mm3. Socio-
demographic correlates of nonadherence have been studied
extensively in HIV-infected patients, and others have linked
nonadherence to non-white race, alcohol and illicit drug use,
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Table 4. Longitudinal GEE Analyses of Depression and Other Factors Associated
with Nonadherence to Antiretroviral Therapy, SUN Study, 2004–2008
Univariate Multivariable
OR 95% CI OR 95% CI
Age (baseline), years
< 35 Referent Referent
35–44 1.12 0.82, 1.52
‡ 45 0.82 0.60, 1.14
Sex
Male Referent Referent Referent Referent
Female 2.09 1.62, 2.69a 1.71 1.28, 2.28a
Race/ethnicity
Non-Hispanic black 2.12 1.64, 2.73a 1.59 1.18, 2.14a
Hispanic/other 1.68 1.19, 2.36a 1.49 1.04, 2.14a
Non-Hispanic white Referent Referent Referent Referent
Partner statusb
Alone 1.15 0.91, 1.45
Partner or unknown Referent Referent
Employment status (closest)c
Full time Referent Referent Referent Referent
Part time 1.33 0.93, 1.91 1.06 0.73, 1.54
Unemployed 2.48 1.84, 3.36a 1.36 0.96, 1.93
Retired or other 1.21 0.90, 1.64 0.60 0.42, 0.87a
HIV risk group
Heterosexual 1.82 1.40, 2.36a
IVDU 2.43 1.60, 3.70a
MSM Referent Referent
Other or unknown 1.45 0.95, 2.21
Insurance status (baseline)
Private or other Referent Referent
Public 1.73 1.37, 2.19a
Current tobacco use
No Referent Referent Referent Referent
Yes 1.92 1.52, 2.41a 1.66 1.28, 2.15a
Drug use past 6 months
Yes 1.29 1.03, 1.62a
No Referent Referent
Alcohol use past 30 days
< 3 drinks/day Referent Referent Referent Referent
3 or more drinks/day 1.69 1.33, 2.16a 1.66 1.28, 2.15a
BMI, kg/m3
< 25 Referent Referent
25–29.9 0.80 0.62, 1.03
‡ 30 0.83 0.61, 1.14
CD4 count, cells/mm3
< 200 3.16 2.14, 4.64a 3.13 2.07, 4.73a
200–349 1.26 0.93, 1.72 1.25 0.90, 1.74
350–500 1.22 0.91, 1.63 1.23 0.90, 1.66
> 500 Referent Referent Referent Referent
HCV (baseline)
No Referent Referent
Yes 1.81 1.35, 2.43a
Prescribed antidepressant in the past 6 months
Yes 1.13 0.80, 1.59
No Referent Referent
Duration since HIV diagnosis (baseline)
< 5 years Referent Referent Referent Referent
‡ 5 years 1.33 1.06, 1.67a 1.45 1.13, 1.86a
Depression by PRIME-MD (closest)c
None Referent Referent Referent Referent
Mild or moderate 2.52 1.42, 4.28a 2.02 1.15, 3.57a
Moderately severe or severe 2.14 1.52, 3.00a 1.74 1.19, 2.56a
aStatistically significant association at p< 0.05; bIncludes marital status. Persons married or with a partner are categorized as having a
partner; c‘‘Closest’’: means that data for this variable were taken from the same (6-monthly) ACASI evaluation as the data for the depression
outcome; for VL and CD4, closest values were taken from the medical record (-1 year to+ 3 month window).
ARV, antiretroviral therapy; BMI, body mass index; HCV, hepatitis C virus; IDVU, injection drug users; MSM, men who have sex with
men.
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and longer duration of HIV infection. In a previously reported
baseline cross-sectional analysis in the SUN Study cohort,
nonadherence has been associated with black race, unem-
ployment, HIV diagnosis ‡ 5 years , drinking 3 or more alco-
holic beverages per day, and having not engaged in aerobic
exercise in the last 30 days.56
The association of depression with nonadherence to ARVs in
our study is also consistent with findings from prior studies,
which used a variety of methods for ascertaining depres-
sion.22,57–59 Indeed, depression of any severity observed among
SUN Study participants was associated with nonadherence;
even mild and moderate levels of depression doubled the odds
of reporting nonadherence. Given the increased risk for HIV
disease progression and mortality (due to AIDS-related and
non-AIDS-related causes) associatedwith suboptimal adherence
and lack of virologic suppression, these findings are concerning.
In this study, we administered the PRIME-MD standard
depression screening instrument as part of an ACASI per-
formed in the primary HIV care setting. The self-administra-
tion aspect of the technology enabled the collection of data in
busy clinical settings as well as the ability to interview Spanish
speaking patients. Such longitudinal data in a diverse popu-
lation have not been described extensively. The data collected
by ACASI are valuable in the management of HIV-infected
patients, providing the ability to screen and identify depressed
patients, elicit correlates of depression, and assess the potential
impact of depression on adherence to prescribed care.
Our findings are subject to several limitations. Even in these
integrated care settings, 28.9% of participants did not com-
plete all the required visits and scheduled ACASIs. Loss to
follow-up and resultant missing data could introduce a bias,
particularly in the observed association of depression and
nonadherence. In the SUN Study, the documentation of di-
agnoses of depression in medical charts was not standardized
across participating sites. Participants could also have been
receiving mental health services elsewhere and these data
were not captured in their clinical record at the study clinic.
Because of incomplete medical charting, we could not reliably
ascertain the utility of using PRIME-MD for improving the
diagnosis of depression in routine HIV clinical practice. Ad-
ditionally, although the PRIME-MD instrument was devel-
oped to provide diagnostic criteria for depression and has
been validated, it is possible that participants who reported
depression on PRIME-MD might not have met the criteria for
clinical diagnosis of depression by a physician.60 Further-
more, because no systematic interventions based on PRIME-
MD results were implemented (i.e., clinicians were blinded to
the patients’ individual responses and could not use these
data to assess and treat), we could not evaluate whether rec-
ognition and treatment of depressed patients at high risk for
nonadherence could result in better immunologic and viro-
logic outcomes, as has been suggested previously.31
Collection of depression, nonadherence, and other patient
risk factor data in a confidential fashion through ACASI
compared to other self-report instruments or specific inter-
view methods has been reported in only a limited number of
U.S. HIV cohort studies.11,19,39 While findings to date tend to
be consistent in cross-sectional versus longitudinal analyses of
depression and adherence, the SUN cohort is one of few
studies that provides ongoing data collection from a diverse
cohort in a high-resource setting. This study underscores the
observation that depression and adherence are dynamic
processes that vary over time. One potential application for
future research is to evaluate the real time integration of an
ACASI-based PRIME-MD screening with an on-site behav-
ioral health consultant or specific behavioral intervention and
systematic monitoring of changes in adherence.
In summary, the use of a confidential standardized com-
puter-based screening instrument identified depression in over
10% of men and over 20% of women prescribed HAART; these
persons were in turn at higher risk of nonadherence to anti-
retroviral therapy and of not suppressing plasma HIV
FIG. 2. Percentage of patients with suppressed viral load (< 400 copies/mL) by depression level and follow-up time, SUN
Study, 2004–2006.
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replication. Our findings and those of others suggest that
treating depression would not only improve quality of life but
would also likely improve survival by increasing adherence to
HAART, viral suppression, and CD4 cell counts. Improvement
in health outcomes for the HIV-infected community through
systematic attention to depression can also achieve one of the
goals of the current United States HIV/AIDS strategy.61 Al-
thoughwe could not determinewhether depressionwas under-
diagnosed in our population, we believe our findings provide
further compelling evidence for ensuring that contemporary
HIV-infected patients who are engaged in care are regularly
screened for depression and treated, if indicated.
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